Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Ginkgo Bioworks stock downgraded to by William Blair as performance concerns arise

EditorEmilio Ghigini
Published 05/10/2024, 09:38 AM
DNA
-

On Friday, William Blair issued a downgrade for Ginkgo Bioworks Holdings Inc (NYSE: NYSE:DNA) stock, changing its rating from Market Perform to Underperform. The firm highlighted concerns over the company's quarter performance and its shift in business strategy, which includes moving away from intellectual property (IP) ownership and value share.

The analyst pointed out that Ginkgo's recent quarter results showed a miss in Cell Engineering and a reduction in guidance, which continues a pattern of the company not meeting its own forecasts. This trend has raised doubts about Ginkgo's ability to execute its business plans effectively.

The analyst also noted that the company's decision to stop focusing on IP ownership could eliminate potential revenue from milestones and royalties that were once considered a significant part of Ginkgo's value.

Furthermore, the removal of Cell Engineering program adds as a key performance indicator (KPI) without introducing a new volume KPI presents challenges in assessing the company's market traction and customer growth.

While cost control measures were acknowledged positively, especially in the current economic climate, the analyst expressed a lack of confidence in Ginkgo's ability to achieve its stated targets.

The downgrade comes as Ginkgo's shares are trading at a premium compared to peers, with a multiple of 7.6 times the firm's 2024 Cell Engineering sales target. This is notably higher than the life science tools and contract research organizations (CROs) peers, which trade at 4.0 times and 3.5 times, respectively.

The new Underperform rating reflects the firm's cautious stance on the stock until Ginkgo provides clearer insights into its long-term strategy and demonstrates more consistent and measurable performance metrics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.